David M. O'Malley, MD
Associate Professor
The Ohio State University, James Cancer Hospital
Dept. of OB/GYN
410 W 10th Ave
Columbus,
OH
USA
43210
Biographical Sketch: over 50 peer reviewed publication, national clinical trial PI"
Papers:
45
Clinicopathologic features associated with defective DNA mismatch repair (MMR): a GOG0210 cohort study of 1041 endometrioid endometrial cancer cases
51
A Phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab, and veliparib (ABT-888) in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: a Gynecologic Oncology Group study
89
Adherence to a standard algorithm results in high negative predictive value of sentinel lymph node assessment using indocyanine green (ICG) and isosulfane blue (ISB) dye in endometrial cancer
94
Setting the bar: compliance with ovarian cancer quality indicators at a National Cancer Institute (NCI)-designated Comprehensive Cancer Center (CCC)
95
The use of NCCN guideline therapy in the first line/adjuvant setting in patients with ovarian cancer from 6 NCCN Institutions
208
Outcomes in stage III endometrial cancer are similar for chemotherapy +/- radiation in low and high risk histology
364
Outpatient rapid desensitization for gynecologic oncology patients with moderate to severe hypersensitivity reactions to platinums
Remarks of an introductory nature
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination with Bevacizumab Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian